10.1038/s41386-019-0380-1 Neuropsychopharmacology 59 IadarolaN
Semaglutide, another modified analog of human GLP-1, is resistant to DPP-4 degradation, which enables a once-weekly injection (Lau et al., 2015)
Corporate spin-off, M&A: A conversation with Carrier CEO David Gitlin Carrier Chairman & CEO David Gitlin speaks with Mitch Berlin, EY Americas Vice Chair, EY-Parthenon on acquisition and financial strategy
This may help to reduce gut-related discomfort associated with many sweeteners
Ozempic is already approved to lower the risk of heart attack, death or stroke in adults with type 2 diabetes and heart disease
While drug developers work to mitigate the side effects associated with GLP-1based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment